Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer (vol 5, e225394, 2022)

被引：1
|
作者：
Graf, R. P.
Fisher, V
Weberpals, J.
机构：
来源：
JAMA NETWORK OPEN | 2022年 / 5卷 / 05期
关键词：
D O I：
10.1001/jamanetworkopen.2022.13901
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
    Graf, Ryon P.
    Fisher, Virginia
    Weberpals, Janick
    Gjoerup, Ole
    Tierno, Marni B.
    Huang, Richard S. P.
    Sayegh, Nicolas
    Lin, Douglas, I
    Raskina, Kira
    Schrock, Alexa B.
    Severson, Eric
    Haberberger, James F.
    Ross, Jeffrey S.
    Creeden, James
    Levy, Mia A.
    Alexander, Brian M.
    Oxnard, Geoffrey R.
    Agarwal, Neeraj
    JAMA NETWORK OPEN, 2022, 5 (03)
  • [2] Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition
    Zang, Peter D.
    Chawla, Neal S.
    Barragan-Carrillo, Regina
    Chehrazi-Raffle, Alex
    Tripathi, Abhishek
    Pal, Sumanta K.
    Dorff, Tanya B.
    JAMA ONCOLOGY, 2024, 10 (04) : 531 - 532
  • [3] Metastatic castration-resistant prostate cancer and immune checkpoint inhibitors
    Pavlov, A. Yu.
    Dzidzaria, A. G.
    Gafanov, R. A.
    Samusevich, V. A.
    Mirzoev, E. E.
    Kortyshkova, A. O.
    Aivazov, M. T.
    Mirzoev, F. E.
    ONKOUROLOGIYA, 2024, 20 (01): : 153 - 163
  • [4] Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
    Lanka, Sree M.
    Zorko, Nicholas A.
    Antonarakis, Emmanuel S.
    Barata, Pedro C.
    CURRENT ONCOLOGY, 2023, 30 (04) : 4246 - 4256
  • [5] Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
    Wu, Zixi
    Zhang, Junbiao
    Li, Le
    Wang, Zhihua
    Yang, Chunguang
    ANNALS OF MEDICINE, 2025, 57 (01)
  • [6] Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras, Vicenc
    Pardo, Juan Carlos
    Notario, Lucia
    Etxaniz, Olatz
    Font, Albert
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
  • [7] Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
    Quintanilha, Julia C. F.
    Graf, Ryon P.
    Fisher, Virginia A.
    Oxnard, Geoffrey R.
    Ellis, Haley
    Panarelli, Nicole
    Lin, Douglas I.
    Li, Gerald
    Huang, Richard S. P.
    Ross, Jeffrey S.
    Myer, Parvathi A.
    Klempner, Samuel J.
    JAMA NETWORK OPEN, 2023, 6 (01) : e2252244
  • [8] Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study.
    Sayegh, Nicolas
    Graf, Ryon
    Fisher, Virginia
    Weberpals, Janick
    Huang, Richard S. P.
    Lin, Douglas I.
    Gjoerup, Ole
    Raskina, Kira
    Severson, Eric Allan
    Haberberger, James
    Ross, Jeffrey S.
    Alexander, Brian Michael
    Levy, Mia Alyce
    Oxnard, Geoffrey R.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [9] The efficacy and safety of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
    Wang, Xing-Hui
    Wang, Zhi-Qiang
    Mu, Zhen-Yu
    Zhu, Li-Ping
    Zhong, Chong-Fu
    Guo, Shanchun
    MEDICINE, 2022, 101 (31) : E29715
  • [10] Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
    Li, Pei-Yu
    Lu, Ying-Hao
    Chen, Chung-Yu
    FRONTIERS IN ONCOLOGY, 2022, 12
12345